01 Increasing Prevalence of Chronic Kidney Disease (ckd) The rising incidence of chronic kidney disease (CKD) globally is a primary driver of the end-stage renal disease (ESRD) market. As of 2023, the global prevalence of CKD is estimated to be around 9.1% of the global population, which translates to approximately 700 million people affected worldwide. The surging aging population, which is more susceptible to CKD, further exacerbates this trend.In the United States alone, the Centers for Disease Control and Prevention (CDC) reported that approximately 15% of adults, or 37 million people, have CKD. This increase in CKD cases directly translates to a higher number of ESRD cases, as CKD is a significant risk factor for ESRD. The demand for dialysis, kidney transplants, and other ESRD treatments is rising, boosting the market's growth. Additionally, the lack of widespread awareness and preventive measures for CKD contributes to its progression to ESRD, thereby driving market demand for advanced renal care solutions.
01 High Cost of Treatment and Limited Access to Healthcare The high cost of ESRD treatment poses a significant restraint on the market. Dialysis and kidney transplantation are expensive, long-term treatments that impose a substantial financial burden on patients and healthcare systems. According to the United States Renal Data System (USRDS), the annual per-person cost of hemodialysis is approximately $90,000, while the cost of a kidney transplant can exceed $400,000, including pre- and post-transplant care. These costs are often prohibitive, especially in low- and middle-income nations where healthcare resources are limited.Additionally, limited access to healthcare facilities and trained medical professionals in rural and underdeveloped regions further hampers the market growth. In many parts of Africa and Asia, for instance, the lack of dialysis centers and nephrologists means that many patients do not receive timely and adequate treatment, leading to higher mortality rates. This disparity in access to treatment highlights the need for policies that can subsidize costs and improve healthcare infrastructure globally.
01 Technological Advancements in Renal Replacement Therapies Technological innovations in renal replacement therapies, such as hemodialysis, peritoneal dialysis, and kidney transplantation, are significantly propelling the ESRD market. Recent advancements include wearable and portable dialysis machines, which offer greater flexibility and improve the quality of life for ESRD patients. For instance, the development of the Wearable Artificial Kidney (WAK) by the University of Washington has shown promising results in clinical trials, offering continuous dialysis in a compact, user-friendly device.Furthermore, advancements in biocompatible dialysis membranes and improved dialysate solutions have enhanced the efficiency and safety of dialysis procedures. Innovations in kidney transplant techniques, such as robotic-assisted surgeries and advancements in immunosuppressive drugs, have increased the success rates of transplants and reduced the incidence of graft rejection. These technological strides not only improve patient outcomes but also create opportunities for market growth by making renal replacement therapies more accessible and effective.
July 2026 Vera Therapeutics received U.S. FDA approval for Trutakna for the treatment of Immunoglobulin A Nephropathy (IgAN), expanding the portfolio of therapies aimed at slowing progression to kidney failure and end-stage renal disease.
May 2026 Outset Medical launched the TabloCart with Prefiltration in the U.S., expanding the capabilities of its Tablo Hemodialysis System to support more complex acute dialysis patients in hospital settings.
June 2025 NxStage Medical (a Fresenius Medical Care company) introduced enhancements to its home hemodialysis platform and digital patient management capabilities to improve home-based renal replacement therapy and patient monitoring.
May 2025 scPharmaceuticals received expanded U.S. FDA approval for Furoscix (furosemide injection) to include edema associated with chronic kidney disease, including nephrotic syndrome, broadening treatment options for patients at risk of progression to ESRD.